

**S1 Table.** Comparison of baseline characteristics according to the medication types (non-user, partial and full medication) in overall population

Variable	Group 1 (for prostate cancer) (n=143,870)			Group 2 (for kidney cancer) (n=320,861)			Group 3 (for urothelial cancer) (n=320,613)		
	Non-user	Partial	Full	Non-user	Partial	Full	Non-user	Partial	Full
No. of individuals (%)	22,943 (15.9)	113,291 (78.8)	7,636 (5.3)	41,894 (13.1)	260,067 (81.0)	18,900 (5.9)	41,743 (13.0)	259,975 (81.1)	18,895 (5.9)
Age distribution (yr)									
40-50	10,641 (46.4)	50,194 (44.3)	1,149 (15.1)	19,441 (46.4)	109,571 (42.1)	2,136 (11.3)	19,426 (46.5)	109,572 (42.2)	2,133 (11.3)
50-60	6,093 (26.5)	29,723 (26.2)	2,133 (27.9)	10,337 (24.7)	66,613 (25.6)	4,808 (25.4)	10,316 (24.7)	66,596 (25.6)	7,014 (37.1)
60-70	4,128 (18.0)	22,696 (20.0)	2,720 (35.6)	7,064 (16.9)	52,803 (20.3)	7,014 (37.1)	7,021 (16.8)	52,772 (20.3)	4,940 (26.1)
> 70	2,081 (9.0)	10,678 (9.4)	1,634 (21.4)	5,052 (12.0)	31,080 (12.0)	4,942 (26.2)	4,980 (11.9)	31,035 (11.9)	18,840 (99.7)
Sex									
Female	-	-	-	23,601 (56.3)	113,912 (43.8)	7,743 (41.0)	23,476 (56.2)	113,851 (43.8)	7,740 (41.0)
Male	22,943 (15.9)	113,291 (78.8)	7,636 (5.3)	18,293 (43.7)	146,155 (56.2)	11,157 (59.0)	18,267 (43.8)	146,124 (56.2)	11,155 (59.0)
Insurance eligibility status									
National Health Insurance	22,707 (98.9)	112,884 (99.6)	7,611 (99.7)	41,355 (98.7)	258,778 (99.5)	18,845 (99.7)	41,205 (98.7)	258,688 (99.5)	18,840 (99.7)
Medical aid	236 (1.1)	407 (0.4)	25 (0.3)	539 (1.3)	1,289 (0.5)	55 (0.3)	538 (1.3)	1,287 (0.5)	55 (0.3)
Charlson Comorbidity Index									
0	17,337 (75.6)	84,567 (74.7)	2,294 (30.0)	31,942 (76.2)	189,331 (72.8)	5,458 (28.9)	31,914 (76.5)	189,282 (72.8)	5,458 (28.9)
1	4,153 (18.1)	21,573 (19.0)	3,426 (44.9)	7,248 (17.3)	52,996 (20.4)	8,514 (45.0)	7,234 (17.3)	52,966 (20.4)	8,514 (45.1)
2	1,058 (4.6)	5,259 (4.6)	1,300 (17.0)	1,951 (4.7)	13,319 (5.1)	3,335 (17.7)	1,879 (4.5)	13,307 (5.1)	3,333 (17.6)
≥ 3	395 (1.7)	1,892 (1.7)	616 (8.1)	753 (1.8)	4,421 (1.7)	1,593 (8.4)	716 (1.7)	4,420 (1.7)	1,590 (8.4)
Participant's income level									
1-4	6,156 (26.8)	29,340 (25.9)	1,898 (24.9)	11,832 (28.2)	75,031 (28.9)	5,162 (27.3)	11,792 (28.3)	74,993 (28.9)	5,164 (27.3)
5-8	8,969 (39.1)	46,200 (40.8)	2,880 (37.7)	15,919 (38.0)	102,231 (39.3)	7,021 (37.2)	15,865 (38.0)	102,213 (39.3)	7,017 (37.2)
9-10	7,818 (34.1)	37,751 (33.3)	2,858 (37.4)	14,143 (33.8)	82,805 (31.8)	6,717 (35.5)	14,086 (33.7)	82,769 (31.8)	6,714 (35.5)
No. of cancer development (2003-2013)									
Total	1,163 (5.1)	7,640 (6.7)	819 (10.7)	138 (0.3)	850 (0.3)	119 (0.6)	276 (0.7)	1,660 (0.6)	185 (1.0)
Person-year (/100,000/yr)	79.3	674.3	1072.5	32.9	32.7	62.9	66.1	63.8	97.9
No. of death (2003-2013)									
All-cause death	182	1,060	171	32	155	35	74	372	56
Cancer-specific death	23	123	18	15	53	13	20	122	12

Values are presented as number (%)